2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
Who is this study for? Patients with familial hypercholesterolemia
What treatments are being studied? 2-Hydroxybenzylamine
Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 69
Healthy Volunteers: f
View:
• Individuals with heterozygous Familial Hypercholesterolemia.
Locations
United States
Tennessee
Vanderbilt University Medical Center
RECRUITING
Nashville
Contact Information
Primary
Anca Ifrim, RN
anca.ifrim@vumc.org
6155224210
Time Frame
Start Date: 2024-02-14
Estimated Completion Date: 2025-12
Participants
Target number of participants: 72
Treatments
Active_comparator: 2-Hydroxybenzylamine (2-HOBA)
2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
Placebo_comparator: Placebo
Placebo- three tabs TID (po) for 6 weeks.
Related Therapeutic Areas
Sponsors
Leads: Vanderbilt University Medical Center
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)